Skip to main content

Advertisement

SpringerLink
Log in

The latest research trends in primary biliary cholangitis: a bibliometric analysis

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

The bibliometric analysis uses the citation count of an article to measure its impact in the scientific community, but no study has been undertaken to determine the most influential papers in the field of primary biliary cholangitis (PBC). This study aimed to investigate the global research interest regarding PBC in dentistry using a bibliometric approach. We searched the Web of Science Core Collection database to find the top 100 most cited (T100) articles focusing on PBC. The information about each article including citations, authors, journals, countries, institutions, and keywords was recorded for bibliometric analysis. The T100 articles related to PBC were published from 1983 to 2019 and were originated from 26 countries. A total of 805 different authors were from 342 different institutions, and articles written by them were published in 35 journals. The five most frequently occurring keywords were “biochemical response,” “ursodeoxycholic acid,” “primary biliary cirrhosis,” “antimitochondrial antibody,” and “autoimmunity.” The T100 articles were classified into different research focuses: pathogenesis (41%), treatment (20%), prognosis (12%), epidemiology (9%), diagnosis (8%), and others (10%). These 100 articles included 32 observational studies, 29 basic research articles, 15 reviews, eight meta-analyses, 12 clinical trials, and four clinical guidelines. The 100 top-cited articles are marked with the leading countries, institutions, journals, hotspots, and development trends in the PBC field that could provide the foundation for further investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Tsuneyama K, Baba H, Morimoto Y, Tsunematsu T, Ogawa H. Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms. J Med Investig. 2017;64(12):7–13. https://doi.org/10.2152/jmi.64.7.

    Article  Google Scholar 

  2. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from “cirrhosis” to “cholangitis.” Gastroenterology. 2015;149(6):1627–9. https://doi.org/10.1053/j.gastro.2015.08.031.

    Article  PubMed  Google Scholar 

  3. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386(10003):1565–75. https://doi.org/10.1016/s0140-6736(15)00154-3.

    Article  CAS  PubMed  Google Scholar 

  4. Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568–94. https://doi.org/10.1136/gutjnl-2017-315259.

    Article  CAS  PubMed  Google Scholar 

  5. Pandit S, Samant H (2021) Primary biliary cholangitis. In StatPearls. Copyright© 2021, StatPearls Publishing LLC

  6. Carbone M, Nardi A, Flack S, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA response score. Lancet Gastroenterol Hepatol. 2018;3(9):626–34. https://doi.org/10.1016/s2468-1253(18)30163-8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jin B, Wu X, Xu G, et al. Evolutions of the management of colorectal cancer liver metastasis: a bibliometric analysis. J Cancer. 2021;12(12):3660–70. https://doi.org/10.7150/jca.52842.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Powell AG, Hughes DL, Wheat JR, Lewis WG. The 100 most influential manuscripts in gastric cancer: a bibliometric analysis. Int J Surg. 2016;28:83–90. https://doi.org/10.1016/j.ijsu.2016.02.028.

    Article  PubMed  Google Scholar 

  9. Murray MR, Wang T, Schroeder GD, Hsu WK. The 100 most cited spine articles. Eur Spine J. 2012;21(10):2059–69. https://doi.org/10.1007/s00586-012-2303-2.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Qin B, Liang Y, Yang Z, Zhong R. Scientific publications on primary biliary cirrhosis from 2000 through 2010: an 11-year survey of the literature. PLoS ONE. 2012;7(4):e35366. https://doi.org/10.1371/journal.pone.0035366.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yu Y, Li Y, Zhang Z, et al. A bibliometric analysis using VOSviewer of publications on COVID-19. Ann Transl Med. 2020;8(13):816. https://doi.org/10.21037/atm-20-4235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. https://doi.org/10.1007/s11192-009-0146-3.

    Article  PubMed  Google Scholar 

  13. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308. https://doi.org/10.1002/hep.22906.

    Article  PubMed  Google Scholar 

  14. Moritoki Y, Zhang W, Tsuneyama K, et al. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology. 2009;136(3):1037–47. https://doi.org/10.1053/j.gastro.2008.11.035.

    Article  CAS  PubMed  Google Scholar 

  15. Hamlyn AN, Macklon AF, James O. Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality. Gut. 1983;24(10):940–5. https://doi.org/10.1136/gut.24.10.940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hwang JW, Kim H, Lee DJ. The 100 most influential manuscripts on hepatocellular carcinoma: a bibliometric analysis. J Int Med Res. 2019;47(4):1467–82. https://doi.org/10.1177/0300060519835974.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–43. https://doi.org/10.1056/NEJMoa1509840.

    Article  CAS  PubMed  Google Scholar 

  18. Corpechot C, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378(23):2171–81. https://doi.org/10.1056/NEJMoa1714519.

    Article  CAS  PubMed  Google Scholar 

  19. Shuaib W, Acevedo JN, Khan MS, Santiago LJ, Gaeta TJ. The top 100 cited articles published in emergency medicine journals. Am J Emerg Med. 2015;33(8):1066–71. https://doi.org/10.1016/j.ajem.2015.04.047.

    Article  PubMed  Google Scholar 

  20. Tian J, Li M, Lian F, Tong X. The hundred most-cited publications in microbiota of diabetes research: a bibliometric analysis. Medicine (Baltimore). 2017;96(37):e7338. https://doi.org/10.1097/md.0000000000007338.

    Article  PubMed  Google Scholar 

  21. Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet. 2020;396(10266):1915–26. https://doi.org/10.1016/s0140-6736(20)31607-x.

    Article  CAS  PubMed  Google Scholar 

  22. Shimoda S, van de Water J, Ansari A, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Investig. 1998;102:1831–40. https://doi.org/10.1172/jci4213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Li Y, Tang R, Ma X. Epigenetics of primary biliary cholangitis. Adv Exp Med Biol. 2020;1253:259–83. https://doi.org/10.1007/978-981-15-3449-2_10.

    Article  CAS  PubMed  Google Scholar 

  24. Juran BD, Hirschfield GM, Invernizzi P, et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet. 2012;21(23):5209–21. https://doi.org/10.1093/hmg/dds359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lan RY, Salunga TL, Tsuneyama K, et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun. 2009;32(1):43–51. https://doi.org/10.1016/j.jaut.2008.11.001.

    Article  CAS  PubMed  Google Scholar 

  26. Yang CY, Ma X, Tsuneyama K, et al. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology. 2014;59(5):1944–53. https://doi.org/10.1002/hep.26979.

    Article  CAS  PubMed  Google Scholar 

  27. Qiu F, Tang R, Zuo X, et al. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nat Commun. 2017;8:14828. https://doi.org/10.1038/ncomms14828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2015;42(8):655–7. https://doi.org/10.1038/ng.631.

    Article  CAS  Google Scholar 

  29. Selmi C, Meda F, Kasangian A, et al. Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. Cell Mol Immunol. 2010;7(1):1–10. https://doi.org/10.1038/cmi.2009.104.

    Article  PubMed  Google Scholar 

  30. Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010;59(4):508–12. https://doi.org/10.1136/gut.2009.184218.

    Article  CAS  PubMed  Google Scholar 

  31. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–8. https://doi.org/10.1016/j.jhep.2011.10.025.

    Article  PubMed  Google Scholar 

  32. Mason AL, Zhang G. Linking human beta retrovirus infection with primary biliary cirrhosis. Gastroenterol Clin Biol. 2010;34(6–7):359–66. https://doi.org/10.1016/j.gcb.2010.04.014.

    Article  CAS  PubMed  Google Scholar 

  33. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42(5):1194–202. https://doi.org/10.1002/hep.20907.

    Article  PubMed  Google Scholar 

  34. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet. 1965;1(7390):827–31. https://doi.org/10.1016/s0140-6736(65)91372-3.

    Article  CAS  PubMed  Google Scholar 

  35. Li CP, Hwang SJ, Chan CY, et al. Clinical evaluation of primary biliary cirrhosis in Chinese patients without serum anti-mitochondrial antibody. Zhonghua Yi Xue Za Zhi (Taipei). 1997;59(6):334–40.

    CAS  PubMed  Google Scholar 

  36. Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology. 1997;25(5):1090–5. https://doi.org/10.1002/hep.510250507.

    Article  CAS  PubMed  Google Scholar 

  37. Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology. 1990;12(1):98–105. https://doi.org/10.1002/hep.1840120116.

    Article  CAS  PubMed  Google Scholar 

  38. Zhang Q, Liu Z, Wu S, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Gastroenterol Res Pract. 2019. https://doi.org/10.1155/2019/8959103.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Bogdanos DP, Baum H, Butler P, et al. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis. 2003;35(11):801–5. https://doi.org/10.1016/s1590-8658(03)00466-3.

    Article  CAS  PubMed  Google Scholar 

  40. Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: what do autoantibodies tell us? World J Gastroenterol. 2010;16(29):3616–29. https://doi.org/10.3748/wjg.v16.i29.3616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United Eur Gastroenterol J. 2020;8(6):667–74. https://doi.org/10.1177/2050640620919585.

    Article  Google Scholar 

  42. Huang YQ. Recent advances in the diagnosis and treatment of primary biliary cholangitis. World J Hepatol. 2016;8(33):1419–41. https://doi.org/10.4254/wjh.v8.i33.1419.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Quarneti C, Muratori P, Lalanne C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int. 2015;35(2):636–41. https://doi.org/10.1111/liv.12560.

    Article  PubMed  Google Scholar 

  44. Hegade VS, Mells GF, Lammert C, Juran B, Jones DE. P1152: a comparative study of pruritus in PBC cohorts from UK, USA and Italy. J Hepatol. 2015;62(2):S785–S785.

    Article  Google Scholar 

  45. Newton JL, Hudson M, Tachtatzis P, et al. Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis. Hepatology. 2007;45(6):1496–505. https://doi.org/10.1002/hep.21609.

    Article  PubMed  Google Scholar 

  46. Gu EL, Yao GB. The clinical characteristics of primary biliary cirrhosis in China: a systematic review. Zhonghua Gan Zang Bing Za Zhi. 2009;17(11):861–6.

    PubMed  Google Scholar 

  47. Al-Harthy N, Kumagi T, Coltescu C, Hirschfield GM. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology. 2010;52(2):562–70. https://doi.org/10.1002/hep.23683.

    Article  PubMed  Google Scholar 

  48. Purohit T, Cappell MS. Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy. World J Hepatol. 2015;7(7):926–41. https://doi.org/10.4254/wjh.v7.i7.926.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009;31(3):283–307. https://doi.org/10.1007/s00281-009-0164-5.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871–7. https://doi.org/10.1002/hep.22428.

    Article  CAS  PubMed  Google Scholar 

  51. Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. 2013;108(6):933–41. https://doi.org/10.1038/ajg.2013.51.

    Article  CAS  PubMed  Google Scholar 

  52. Moritoki Y, Lian ZX, Lindor K, et al. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology. 2009;50(6):1893–903. https://doi.org/10.1002/hep.23238.

    Article  CAS  PubMed  Google Scholar 

  53. Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149(7):1804-1812.e4. https://doi.org/10.1053/j.gastro.2015.07.061.

    Article  PubMed  Google Scholar 

  54. Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology (Baltimore, MD). 2016;63(3):930–50. https://doi.org/10.1002/hep.28017.

    Article  CAS  PubMed  Google Scholar 

  55. Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281–7. https://doi.org/10.1053/j.gastro.2009.01.003.

    Article  CAS  PubMed  Google Scholar 

  56. Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361–7. https://doi.org/10.1016/j.jhep.2011.02.031.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the "Natural Science Foundation of Fujian Province, China" (No. 2020J01120297) to Hongbin Chen which provided funds for our research.

Author information

Author notes

  1. Yu Zhao and Zhenjie Yin have contributed equally to this work and share the first authorship.

Authors and Affiliations

  1. Department of Gastroenterology, Affiliated Sanming First Hospital, Fujian Medical University, Sanming, 365001, Fujian, People’s Republic of China

    Yu Zhao, Huang Du, Kangming Huang, Fajing Zhang & Hongbin Chen

  2. Department of Urology, Affiliated Sanming First Hospital, Fujian Medical University, Sanming, 365001, Fujian, People’s Republic of China

    Zhenjie Yin

Authors
  1. Yu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhenjie Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huang Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kangming Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fajing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hongbin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HC, YZ, and ZY designed the study. YZ and ZY conducted the literature search and analyzed the data. YZ drafted the manuscript. HD and KH drew the pictures. ZY and FZ prepared the tables. HC and YZ reviewed and revised the manuscript. All authors contributed to the article and approved the submitted version.

Corresponding author

Correspondence to Hongbin Chen.

Ethics declarations

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 63 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, Y., Yin, Z., Du, H. et al. The latest research trends in primary biliary cholangitis: a bibliometric analysis. Clin Exp Med 23, 347–355 (2023). https://doi.org/10.1007/s10238-022-00825-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-022-00825-0

Keywords

Search

Navigation